Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glaxo: Power brand strategy pays off - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 19, 2004

    Glaxo: Power brand strategy pays off

    GlaxoSmithKline Pharmaceuticals (Glaxo) recently announced its quarter and year ending FY04 results. For 4QFY04, while the topline grew by 8% YoY, the company did well to turn out profits after the losses that it had incurred in the same period of FY03. The profit growth for FY04 was better still at 76% YoY. This came on back of the company improving upon its revenues by 4% for this period. This growth in topline compbined with reduction on the expenditure front helped Glaxo to improve its operating margins for FY04 by 570 basis points. The improvement on the margins front was much better at 1,040 basis points for the fourth quarter.

    Financial performance: A snapshot
    (Rs m) 4QFY03 4QFY04 Change FY03 FY04 Change
    Sales 2,290 2,466 7.7% 11,482 11,917 3.8%
    Other Income 145 161 10.8% 427 544 27.3%
    Expenditure 2,104 2,010 -4.5% 9,751 9,436 -3.2%
    Operating Profit (EBDIT) 186 456 145.7% 1,731 2,481 43.3%
    Operating Profit Margin (%) 8.1% 18.5% - 15.1% 20.8% -
    Interest 0 0 - 0 0 -
    Depreciation 46 49 7.0% 195 179 -7.9%
    Profit before Tax 285 568 99.3% 1,963 2,846 44.9%
    Extraordinary items (251) (219) - (304) (96) -
    Tax 68 202 196.5% 679 1,027 51.3%
    Profit after Tax/(Loss) (35) 146   981 1,722 75.6%
    Net profit margin (%) -1.5% 5.9%   8.5% 14.5%  
    No. of Shares 74.7 74.7   74.7 74.7  
    Diluted Earnings per share* (Rs) -1.9 7.8   13.1 23.1  
    P/E Ratio (x)         27.2  
    (* annualised)            

    The growth in topline for FY04 was a result of the company's pharmaceuticals business growing by 6% YoY. The growth in this business, which constitutes to around 82% of Glaxo's total revenues, negated the 5% decline in revenues from the company's other businesses segment (18% of revenues). This segment caters to areas like veterinary formulations, feed supplements, diagnostics and lab equipments. Growth of the pharmaceuticals segment was driven basically by the 30 priority products (including brands like Augmentin) of the company that registered double-digit growth. Another growth driver from the pharma business was the company's vaccines range where the company rolled out a concept of 'Famili Vaccines' an immunisation awareness initiative.

    Segmental performance
    (Rs m) FY03 FY04 Change
    Revenue 9,401 9,970 6.1%
    PBIT 1,620 2,373 46.5%
    PBIT margins 17.2% 23.8%  
    Other businesses
    Revenue 2,388 2,262 -5.3%
    PBIT 394 445 12.9%
    PBIT margins 16.5% 19.7%  
    Revenue 11,789 12,232 3.8%
    PBIT 2,013 2,818 39.9%
    PBIT margins 17.1% 23.0%  
    * Excluding inter-segment adjustments

    On the profitability front, Glaxo has been able to improve its operating margins by substantial measures. And this is mainly a result of decline on the material consumed and other expenses fronts. While the former declined (as a percentage of sales) by around 2%, the drop in the latter was larger at around 8%. Based on segments, while PBIT margins for the pharmaceuticals segment improved by 660 basis points, the improvement in margins for Glaxo's other businesses was a substantial 320 basis points. The company's stated strategy of focusing on 30 power brands (reminds one of HLL) seems to be bearing fruit and driving profitability.

    Cost break-up
    (Rs m) FY03 FY04 Change
    Materials consumed 5,031 4,943 -1.7%
    % Of sales 43.8% 41.5%  
    Staff costs 1,313 1,301 -0.9%
    % Of sales 11.4% 10.9%  
    Excise duty 1,010 985 -2.4%
    % Of sales 8.8% 8.3%  
    Other expenses 2,497 2,307 -7.6%
    % Of sales 21.7% 19.4%  
    Total expenses* 9,851 9,536 -3.2%
    % Of sales 85.8% 80.0%  
    * Excluding recovery of expenses

    The improvement in Glaxo's FY04 margins would have been better but for the fact that the National Pharmaceuticals Pricing Authority (NPPA) revised downwards the prices of Ranitidine formulations in the third quarter (ending September 2003). This affected the margins of Zinetac, one of the important products of Glaxo.

    At the current price of Rs 627, the stock is trading at a P/E multiple of 27.2x its FY04 earnings. The company has declared a dividend of Rs 10 per equity share for FY04 (Rs 7 in FY03). The company is in advanced stages of negotiations for its Worli property in Mumbai, which is expected to give its extraordinary income a fillip in FY05. Glaxo is gearing itself towards 2005, when the patent regime comes into force. The company is also likely to finalise the much awaited merger with Burroughs Wellcome soon. Though the valuations seem at the upper end of the spectrum, future benefits during the patent regime post 2005 is keeping the investor interest alive.



    Equitymaster requests your view! Post a comment on "Glaxo: Power brand strategy pays off ". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 16, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts